The EU Commission sends statements of objections to two pharmaceutical companies over possible delayed entry of generic (Johnson & Johnson, Novartis)

On 31 January 2013, the European Commission announced that it had sent a Statement of Objections (“SO”) to pharmaceutical companies Johnson & Johnson (“J&J”) and Novartis over

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Van Bael & Bellis (Brussels)

Quotation

Peter L'Ecluse, The EU Commission sends statements of objections to two pharmaceutical companies over possible delayed entry of generic (Johnson & Johnson, Novartis), 31 January 2013, e-Competitions Bulletin Competition in the Pharmaceutical sector, Art. N° 58203

Visites 133

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues